Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
The Journal of Biological Chemistry|July 3, 2003
Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasisAlan Bohan, Wen-Sheng Chen, Lee A Denson, et al.
Cancer Research|January 6, 2010
Characterization of melanoma cells capable of propagating tumors from a single cellMatthew A Held, David P Curley, David Dankort, et al.
Oncotarget|August 27, 2019
Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancerSierra A Colavito, James T Platt, Matthew A Held, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|December 18, 2004
Alterations in growth hormone receptor abundance regulate growth hormone signaling in murine obstructive cholestasisMatthew A Held, Wilfredo Cosme-Blanco, Lisa M Difedele, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|January 10, 2003
Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3Lee A Denson, Matthew A Held, Ram K Menon, et al.
The Journal of Biological Chemistry|October 16, 2008
DYRK3 dual-specificity kinase attenuates erythropoiesis during anemiaOlga Bogacheva, Oleg Bogachev, Madhu Menon, et al.
Gastroenterology|May 12, 2005
Tumor necrosis factor alpha blockade restores growth hormone signaling in murine colitisLisa M DiFedele, Jiman He, Erin L Bonkowski, et al.
Molecular Cancer Therapeutics|May 8, 2015
BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell VolumeNicholas Theodosakis, Matthew A Held, Alexander Marzuka-Alcala, et al.
Cancer Research|November 23, 2016
Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast CancerVikram B Wali, Casey G Langdon, Matthew A Held, et al.
Pigment Cell & Melanoma Research|April 10, 2015
The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitorsCasey G Langdon, Matthew A Held, James T Platt, et al.
Pageof 6